Study record · Semaglutide (injectable)
STEP 9 semaglutide in obesity and knee osteoarthritis
Weight changed -13.7% versus -3.2%; WOMAC pain improved -41.7 versus -27.5 points with placebo.
Key result
Weight changed -13.7% versus -3.2%; WOMAC pain improved -41.7 versus -27.5 points with placebo.
Study details
Study designRandomized double-blind placebo-controlled trial
PhasePhase III
PopulationAdults with obesity and moderate knee osteoarthritis with pain
Sample size407
RouteSubcutaneous
Regimen / exposureSemaglutide 2.4 mg once weekly after escalation
Duration68 weeks
ComparatorPlacebo
Primary endpoint / questionWeight change and WOMAC knee-pain score
Safety resultSerious adverse-event incidence was similar; permanent discontinuation was 6.7% versus 3.0%, mainly GI-related.
Key limitationsPain improvement occurred alongside substantial weight loss; the study does not prove a direct cartilage-healing effect.
Registry / identifierPMID 39476339